SpringerLink
Log in

Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Chemotherapy is the major therapy for cancer in clinic. However, chemotherapeutic agents can harm the other tissues/organs besides cancer. Thus, there are great interests in protecting the innocents by the transfer of protective genes. There are two problems to be solved, one is the selection of protective genes and the other is the orientation of the exotic genes. Recent researches demonstrated that the principal mechanism of chemotherapeutics was through apoptosis. Hereby, introduction of anti-apoptosis genes might interrupt the processes of apoptosis to avoid side effect from chemotherapeutics. On the other hand, tissue-specific promoters, which control gene expression in a tissue-specific manner, might be an alternative tool to guarantee the location of target genes. In this research, we applied gene therapy to chemoprotection using anti-apoptosis gene survivin and ovarian-specific promoter OSP-2. The results showed that OSP-2 could specifically drive the expression of survivin in ovarian cells and survivin could protect cells via inhibiting apoptosis. This might put a light on the future of chemoprotective gene therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Bertino JR (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587(2–3):164–173

    PubMed  CAS  Google Scholar 

  2. Licht T, Goldenberg SK, Vieira WD, Gottesman MM, Pastan I (2000) Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice. Gene Ther 7(4):348–358

    Article  PubMed  CAS  Google Scholar 

  3. Kobayashi H, Takemura Y, Miyachi H (2001) Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum Cell 14(3):172–184

    PubMed  CAS  Google Scholar 

  4. Chinnasamy N, Rafferty JA, Hickson I, Lashford LS, Longhurst SJ, Thatcher N, Margison GP, Dexter TM, Fairbaim LJ (1998) Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene Ther 5(6):842–847

    Article  PubMed  CAS  Google Scholar 

  5. Bagchi S, Raychaudhuri P (2010) Damaged-DNA binding protein-2 drives apoptosis following DNA damage. Cell Div 5:3. doi:10.1186/1747-1028-5-3

    Article  PubMed  Google Scholar 

  6. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000–5005

    Article  PubMed  CAS  Google Scholar 

  7. Fukazawa T, Maeda Y, Durbin ML, Nakai T, Matsuoka J, Tanaka H, Naomoto Y, Tanaka N (2007) Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol Cancer Ther 6(1):244–252

    Article  PubMed  CAS  Google Scholar 

  8. Dorer DE, Nettelbeck DM (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61(7–8):554–571

    Article  PubMed  CAS  Google Scholar 

  9. Tu CH, Liu WP, Huang LL, Mo YQ, Yang DZ (2009) Cloning and transcriptional activity of a novel ovarian-specific promoter from rat retrovirus-like elements. Arch Biochem Biophys 485(1):24–29

    Article  PubMed  CAS  Google Scholar 

  10. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 55–56

    Google Scholar 

  11. Sasaki Y, Saijo N, Lee YC, Takahashi H, Ishihara J, Sakurai M, Sano T, Nakano H, Kanzawa F, Hoshi A, Hamburger AW (1986) A bioassay of cisplatin by human tumor clonogenic assay. Jpn J Cancer Res 77(5):494–501

    PubMed  CAS  Google Scholar 

  12. Siders WM, Halloran PJ, Fenton RG (1998) Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase. Cancer Gene Ther 5(5):281–291

    PubMed  CAS  Google Scholar 

  13. Patterson A, Harris AL (1999) Molecular chemotherapy for breast cancer. Drugs Aging 14(2):75–90

    Article  PubMed  CAS  Google Scholar 

  14. Vandier D, Rixe O, Brenner M, Gouyette A, Besnard F (1998) Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res 58(20):4577–4580

    PubMed  CAS  Google Scholar 

  15. Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW (2000) Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol 4(2):73–82

    Article  PubMed  CAS  Google Scholar 

  16. Saukkonen K, Hemminiki A (2004) Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 4(5):683–696

    Article  PubMed  CAS  Google Scholar 

  17. Wang W, ** B, Li W, Xu CX, Cui FA, Liu B, Yan YF, Liu XX, Wang XL (2010) Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus. Mol Biol Rep 37(7):3239–3247

    Article  PubMed  CAS  Google Scholar 

  18. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20(9):2388–2399

    Article  PubMed  CAS  Google Scholar 

  19. James RI, Warlick CA, Diers MD, Gunther R, Mclvor RS (2000) Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. Blood 96(4):1334–1341

    PubMed  CAS  Google Scholar 

  20. Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26(1):61–66

    Article  PubMed  CAS  Google Scholar 

  21. Zhou Y, Ling XL (2010) Establishment of a cisplatin-induced multidrug resistance cell line SK-Hep 1/DDP. Chin J Cancer 29(2):167–171

    PubMed  Google Scholar 

  22. Dallas NA, **a L, Fan F, Gray MJ, Gaur P, Van Buren G II, Samuel S, Kim MP, Lim SJ, Ellis LM (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69(5):1951–1957

    Article  PubMed  CAS  Google Scholar 

  23. Dohi T, Okada K, **a F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salevsen GS, Reed JC, Altieri DC (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(93):34087–34090

    Article  PubMed  CAS  Google Scholar 

  24. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22(9):1682–1688

    Article  PubMed  CAS  Google Scholar 

  25. Reed JC (2001) The survivin saga goes in vivo. J Clin Investig 108(7):965–969

    Article  PubMed  CAS  Google Scholar 

  26. Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5(2):65–72

    Article  PubMed  CAS  Google Scholar 

  27. Hennessy M, Spiers JP (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55(1):1–15

    Article  PubMed  CAS  Google Scholar 

  28. Adams JM, Corry S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26(1):61–66

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by grants from the New Teacher Fund for the Doctoral Program of Ministry of Education of China (Grant no. 20070558520), the Science Technology Research Project of Guangdong Province (Grant no. 2008B080701026), the Technology Support Project of Jiangxi Province (Grant no. 210DSA14900).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Nanchang, 330006, China

    Chun-Hua Tu & Li-** Cai

  2. Department of Urology, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China

    Wei-Peng Liu

  3. Department of Obstetrics and Gynecology, Memorial Hospital of Sun Yat-Sen University, No. 107 Yanjiang Road, Guangzhou, 510120, China

    Mei Dong, Ya-Qin Mo & Dong-Zi Yang

Authors
  1. Chun-Hua Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-Peng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-** Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ya-Qin Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong-Zi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ya-Qin Mo or Dong-Zi Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tu, CH., Liu, WP., Dong, M. et al. Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2. Mol Biol Rep 38, 2323–2328 (2011). https://doi.org/10.1007/s11033-010-0365-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-010-0365-y

Keywords

Search

Navigation